[
    [
        {
            "time": "",
            "original_text": "权益变动】凯莱英(06821.HK)获FMR LLC增持39.7406万股",
            "features": {
                "keywords": [
                    "凯莱英",
                    "FMR LLC",
                    "增持",
                    "39.7406万股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "权益变动】凯莱英(06821.HK)获FMR LLC增持39.7406万股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "CRO龙头凯莱英跌停带崩赛道",
            "features": {
                "keywords": [
                    "凯莱英",
                    "跌停",
                    "CRO",
                    "赛道"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "CRO龙头凯莱英跌停带崩赛道",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "风禾尽起：中国医药CDMO的机遇与挑战",
            "features": {
                "keywords": [
                    "医药",
                    "CDMO",
                    "机遇",
                    "挑战"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "风禾尽起：中国医药CDMO的机遇与挑战",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "最前线 | 辉瑞口服新冠特效药获FDA紧急授权，美政府采购价约合3370元/疗程",
            "features": {
                "keywords": [
                    "辉瑞",
                    "新冠特效药",
                    "FDA",
                    "紧急授权",
                    "采购价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "最前线 | 辉瑞口服新冠特效药获FDA紧急授权，美政府采购价约合3370元/疗程",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "辉瑞新冠口服药获批上市，其中国合作伙伴引发市场猜想",
            "features": {
                "keywords": [
                    "辉瑞",
                    "新冠口服药",
                    "获批",
                    "合作伙伴",
                    "市场猜想"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "辉瑞新冠口服药获批上市，其中国合作伙伴引发市场猜想",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(06821.HK)获高盛增持12.1万股",
            "features": {
                "keywords": [
                    "凯莱英",
                    "高盛",
                    "增持",
                    "12.1万股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英(06821.HK)获高盛增持12.1万股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]